27 May

10 Years of Simplicity Webcast

27. May 2021

In 2011, Trajenta® (linagliptin) became first approved by regulatory agencies around the world, as a once-daily, always one-dose, DPP4i for the treatment of type 2 diabetes*. For the past 10 years, the simplicity of Trajenta® has helped physicians and patients with the management of type 2 diabetes for a broad range of patients1. In that time, Trajenta® has had more than 20 million patient-years of exposure2, and it continues to be an important tool for healthcare professionals worldwide3.

This year, in commemoration of the past 10 years, we organized a 2-hour webcast, the 10 Years of Simplicity. The event took place on the 27th of May 2021. During the interactive webcast, we discussed Trajenta® and how 10 years of experience have helped simplify the management of type 2 diabetes for physicians and patients worldwide. Participants heard perspectives from leading international experts in the treatment of type 2 diabetes. Continue below to learn more about the event.

Meet the Experts

er Henrik Groop - Chair

Professor

Per-Henrik Groop

Professor and Chair of Internal Medicine at the University of Helsinki and & Chief Physician at the Helsinki University Hospital

Chair
er Henrik Groop - Chair

Doctor

Sarah Jarvis

General Practitioner (GP), GP Trainer and Fellow of the Royal College of General Practitioners (RCGP)

Moderator
er Henrik Groop - Chair

Professor

Clifford J. Bailey

Professor of Clinical Science and Director of Biomedical Sciences Research at Aston University in Birmingham, England

Speaker
er Henrik Groop - Chair

Professor

Nikolaus Marx

Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany

Speaker

Agenda

Download link
12:00 - 12:05

Welcome to 10 Years of  Trajenta®

Per-Henrik Groop and Sarah Jarvis

  • Webcast objectives and introduction of Chair
12:05 - 12:35

10 Years of Improvement in T2D Patient Care

Clifford J. Bailey

  • Chair to introduce faculty
  • Paradigm shift in T2D guidelines based on evidence of proven CV benefit
  • The role of DPP4i in treatment of  T2D and the evolution of the Trajenta® profile (proven efficacy1, convenience, followed by CV and kidney safety from CVOTs)
12:35 - 12:55

CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme

Nikolaus Marx

  • Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of  T2D disease duration, CV and kidney risk
  • Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial
12:55 - 13:15

Can A Broad Range of  T2D Patients Benefit From The Simplicity of Linagliptin?

Per-Henrik Groop

  • Proven efficacy1 for a broad range of patients, and convenience of always one dose, once daily
  • Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme
13:15 - 13:35

Defining Simplicity in Clinical Practice – A Case-Driven Approach

Sarah Jarvis

  • Patient cases incorporating speaker experience with Trajenta®
  • Data from Trajenta® CVOTs support treatment decision making
13:35 - 13:45

Summarising The Advances That Linagliptin Has Brought to T2D Care

Per-Henrik Groop

  • Vast experience with Trajenta®
  • Highlights of Trajenta® simplicity (efficacy, safety, convenience)
13:45 - 14:00

Q&A and Close

Per-Henrik Groop and Sarah Jarvis

  • Audience Q&A
  • Moderator to reinforce the simplicity of Trajenta® and close the webcast
19:00 - 19:05

Welcome to 10 Years of  Trajenta®

Per-Henrik Groop and Sarah Jarvis

  • Webcast objectives and introduction of Chair
19:05 - 19:35

10 Years of Improvement in T2D Patient Care

Clifford J. Bailey

  • Chair to introduce faculty
  • Paradigm shift in T2D guidelines based on evidence of proven CV benefit
  • The role of DPP4i in treatment of  T2D and the evolution of the Trajenta® profile (proven efficacy1, convenience, followed by CV and kidney safety from CVOTs)
19:35 - 19:55

CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme

Nikolaus Marx

  • Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of  T2D disease duration, CV and kidney risk
  • Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial
19:55 - 20:15

Can A Broad Range of  T2D Patients Benefit From The Simplicity of Linagliptin?

Per-Henrik Groop

  • Proven efficacy1 for a broad range of patients, and convenience of always one dose, once daily
  • Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme
20:15 - 20:35

Defining Simplicity in Clinical Practice – A Case-Driven Approach

Sarah Jarvis

  • Patient cases incorporating speaker experience with Trajenta®
  • Data from Trajenta® CVOTs support treatment decision making
20:35 - 20:45

Summarising The Advances That Linagliptin Has Brought to T2D Care

Per-Henrik Groop

  • Vast experience with Trajenta®
  • Highlights of Trajenta® simplicity (efficacy, safety, convenience)
20:45 - 21:00

Q&A and Close

Per-Henrik Groop and Sarah Jarvis

  • Audience Q&A
  • Moderator to reinforce the simplicity of Trajenta® and close the webcast

Footnotes

  • DPP4i: dipeptidyl peptidase-4 inhibitor; T2D: type 2 diabetes
  • * Tradjenta® was approved by the US Food and Drug Administration (FDA) on May 2nd, 2011; Trazenta® was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on July 1st, 2011; Trajenta® was approved by the European Medicines Agency (EMA) on August 23rd, 2011; Trajenta® was approved by Health Canada on October 3rd, 2011; Trajenta® was approved by the Australian Therapeutic Goods Administration (TGA) on October 21st, 2011.
  • Trajenta® EMA Summary of Product Characteristics. October 2019.
  • Boehringer Ingelheim. Data on file.
  • American Diabetes Association. Diabetes Care 2021 Jan; 44 (Supplement 1): S111-S124. https://doi.org/10.2337/ dc21-S009.